Drugs / SNP-610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03468556 | Apr 2026 → Apr 2027 expected | metabolic dysfunction-associated steatohepatitis | Sinew Pharma Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-10-16 | Sinew Pharma Inc. | Results 欣耀SNP-630脂肪肝炎新藥 SCI期刊發表臨床結果 sinewpharma.com ↗
而SNP-610 的開放標示性臨床二期預試驗結果，又獲國際知名 SCI 期刊 Journal of Translational Medicine 接受發表。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-16 | Sinew Pharma Inc. | 欣耀SNP-630脂肪肝炎新藥 SCI期刊發表臨床結果 sinewpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNP-610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03468556 ↗ |
| Route | Oral | “Subjects will take 2 tablets once a day orally for 12 weeks” NCT03468556 ↗ |